KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $498.0 million.

  • Vertex Pharmaceuticals' Cash from Operations fell 1481.35% to $498.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 billion, marking a year-over-year increase of 83719.04%. This contributed to the annual value of $3.6 billion for FY2025, which is 83719.04% up from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Cash from Operations stood at $498.0 million, which was down 1481.35% from $1.2 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Cash from Operations high stood at $1.4 billion for Q3 2024, and its period low was -$3.8 billion during Q2 2024.
  • For the 5-year period, Vertex Pharmaceuticals' Cash from Operations averaged around $672.5 million, with its median value being $955.8 million (2022).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Cash from Operations surged by 67075.61% in 2022, and later tumbled by 43088.86% in 2024.
  • Vertex Pharmaceuticals' Cash from Operations (Quarter) stood at $995.0 million in 2021, then rose by 8.38% to $1.1 billion in 2022, then crashed by 78.25% to $234.6 million in 2023, then soared by 149.19% to $584.6 million in 2024, then dropped by 14.81% to $498.0 million in 2025.
  • Its Cash from Operations stands at $498.0 million for Q4 2025, versus $1.2 billion for Q3 2025 and $1.1 billion for Q2 2025.